Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Table 2 Response rate of epidermal growth factor receptor tyrosine kinase inhibitors according to mutation type and treatment regimen

	CR	PR	SD	PD	p value
Total (n = 363)	1 (0.3)	265 (73.0)	72 (19.8)	25 (6.9)	< 0.001
EGFR mutation types
E19del (n = 175)	1 (0.6)	132 (75.4)	33 (18.9)	9 (5.1)
L858R (n = 154)	0	117 (76.0)	30 (19.5)	7 (4.5)
Uncommon (n = 34)	0	16 (47.1)	9 (26.5)	9 (26.5)
EGFR TKIs					0.914
Afatinib (n = 102)	0	74 (72.5)	21 (20.6)	7 (6.9)
Erlotinib (n = 139)	1 (0.7)	100 (71.9)	29 (20.9)	9 (6.5)
Gefitinib (n = 122)	0	91 (74.6)	22 (18.0)	9 (7.4)

Data are shown as n (%) per each group
CR complete response, PR partial response, SD stable disease, PD progressive disease, E19del exon 19 deletion, L858R L858R point mutation, Uncommon uncommon mutations, EGFR epidermal growth factor receptor, TKIs tyrosine kinase inhibitors

ISSN: 1471-2407